ReviewCurrent diabetes reports2009
Aldosterone and diabetic kidney disease.
Review in Current diabetes reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Molecular Mechanisms of Diabetic Kidney Disease.International journal of molecular sciences · 2022Review
- Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!Reviews of physiology, biochemistry and pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aldosterone plays an important role in salt and water homeostasis and blood pressure control through the classical mineralocorticoid receptor. However, recent findings of the mineralocorticoid receptor in nonepithelial tissues suggest that aldosterone may have additional functions. Significant evidence now exists suggesting that aldosterone directly induces tissue injury. Systemic or local aldosterone has emerged as a multifunctional hormone exhibiting profibrotic and proinflammatory actions that extend beyond the classical hemodynamic effect. The incomplete blockade of the renin-angiotensin-aldosterone system by angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has led to experimental and clinical efforts using aldosterone inhibition. Recently, these efforts have provided us with an expanded understanding of a new pathogenic role for aldosterone in diabetic vascular complications. This article focuses on the role of aldosterone in the pathogenesis of diabetic kidney disease and recent important clinical data supporting the inhibition of aldosterone in treating diabetic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.